Plain-language summary
Pirfenidone is an approved anti-fibrotic drug used in idiopathic pulmonary fibrosis, and its ability to calm overactive fibroblasts makes it attractive wherever scarring does harm. Getting it effectively into skin tissue, however, is difficult. This study used exosomes from human dermal fibroblasts as carriers. The researchers first compared two isolation methods and found that an affinity-based technique produced better-dispersed, higher-purity vesicles than polymer precipitation. They then loaded pirfenidone into the exosomes using a sonication-based active loading method, tuning the process carefully so the vesicles kept their structure; the best formulation encapsulated about 11 percent of the drug by weight. In cell studies, exosomes alone boosted fibroblast migration and proliferation, suggesting vesicles might work as a cell-free therapy on their own. In mice, pirfenidone-loaded exosomes sped wound closure and reduced excessive collagen deposition, steering the extracellular matrix toward a less scarring outcome.
Key findings
- An affinity-based isolation method yielded higher-purity, more homogeneous human dermal fibroblast exosomes than PEG precipitation.
- Pirfenidone was actively loaded into exosomes by controlled sonication, achieving roughly 11 percent encapsulation efficiency while preserving vesicle integrity.
- Exosomes alone enhanced fibroblast migration and proliferation, supporting cell-free wound healing approaches.
- In mice, pirfenidone-loaded exosomes accelerated wound healing and reduced excessive collagen deposition, moderating scar formation.
Original abstract
To facilitate scarless wound healing, developing an anti-scarring treatment that modulates dermal fibroblast activity is a promising strategy, with pirfenidone (PFD) showing potential due to its anti-fibrotic properties by targeting intracellular pathways that regulate collagen disposition. PFD, particularly when delivered via dermal fibroblast-derived exosomes, may further enhance therapeutic effectiveness and promote scarless healing. Two common isolation methods-PEG precipitation and affinity-based techniques-were compared to identify the most efficient approach for obtaining high-purity and relatively homogenous exosomes derived from human dermal fibroblasts. Characterization techniques, including transmission electron microscopy (TEM), atomic force microscopy (AFM), antibody arrays, and enzyme-linked immunosorbent assays (ELISA), confirmed the successful isolation of high-purity exosomes. The affinity-based method demonstrated superior performance, yielding well-dispersed and highly pure exosomes. We optimized the encapsulation and formulation of the antifibrotic compound PFD by exploiting exosomes as a drug delivery platform, employing an active loading method via sonication to enhance encapsulation efficiency (EE%) and loading efficiency (LE%), while carefully controlling the sonication process to preserve exosome integrity. The optimal formulation of PFD-exosomes achieved an EE% of 11.14% ± 1.27% and an LE of 10.01% ± 1.03%, with a particle recovery rate of exosomes at 64.21% ± 8.49% using sonication technique. Then, we investigated how to harness exosomes and PFD-exosomes as innovative strategies for achieving scarless tissue repair in wound healing. Our findings showed that exosomes enhanced fibroblast migration and proliferation, highlighting their potential as a stand-alone cell-free therapy for wound healing. Additionally, this study was ground-breaking in demonstrating that exosomes can improve the efficacy of PFD as a drug carrier, amplifying its anti-fibrotic effects in both in vitro and in vivo models. The in vivo results indicated that PFD-exosomes accelerated wound healing while organizing the extracellular matrix (ECM) by reducing excessive collagen deposition. Overall, PFD-exosomes present an innovative strategy for pre-scarring interventions, offering benefits of enhanced wound healing outcomes while minimizing scarring.
Frequently asked questions
What did this study find?
Pirfenidone is an approved anti-fibrotic drug used in idiopathic pulmonary fibrosis, and its ability to calm overactive fibroblasts makes it attractive wherever scarring does harm. Getting it effectively into skin tissue, however, is difficult. This study used exosomes from human dermal fibroblasts as carriers. The researchers first compared two isolation methods and found that an affinity-based technique produced better-dispersed, higher-purity vesicles than polymer precipitation. They then loaded pirfenidone into the exosomes using a sonication-based active loading method, tuning the process carefully so the vesicles kept their structure; the best formulation encapsulated about 11 percent of the drug by weight. In cell studies, exosomes alone boosted fibroblast migration and proliferation, suggesting vesicles might work as a cell-free therapy on their own. In mice, pirfenidone-loaded exosomes sped wound closure and reduced excessive collagen deposition, steering the extracellular matrix toward a less scarring outcome.
Was this tested in humans or in the laboratory?
This is preclinical work — the findings come from laboratory models, not from human participants.
Where can I read the original paper?
The full text lives with the publisher: https://doi.org/10.1007/s13346-026-02108-7
How to cite this paper
Wang Jin, Sun Chen, Ho Emmanuel A. Pirfenidone-exosomes as innovative strategies for scarless tissue repair in wound healing.. Drug delivery and translational research. 2026, 2026-04-13. DOI: 10.1007/s13346-026-02108-7
Source & verification
- Journal: Drug delivery and translational research
- Published: 13 April 2026
- DOI: 10.1007/s13346-026-02108-7
- PubMed ID: 41973317
- Indexed via: pubmed
- MeSH terms: Pyridones, Exosomes, Wound Healing, Humans, Fibroblasts, Animals, Cicatrix, Mice, Cells, Cultured, Cell Movement